Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Hong Kong
/
Pharmaceuticals & Biotech
/
Ascentage Pharma Group International
6855
6855
Ascentage Pharma Group International
Takeda Payments Will Undermine Revenue Amid China NRDL Pressures
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
07 Aug 25
Updated
10 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
HK$51.97
55.9% overvalued
intrinsic discount
10 Aug
HK$81.00
Loading
1Y
179.3%
7D
-3.1%
Author's Valuation
HK$52.0
55.9% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
HK$52.0
55.9% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-1b
981m
2016
2018
2020
2022
2024
2025
2026
2028
Revenue CN¥734.1m
Earnings CN¥136.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
22.99%
Biotech revenue growth rate
11.40%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.89%
Calculation
CN¥136.69m
Earnings '28
x
136.63x
PE Ratio '28
=
CN¥18.68b
Market Cap '28
CN¥18.68b
Market Cap '28
/
321.52m
No. shares '28
=
CN¥58.09
Share Price '28
CN¥58.09
Share Price '28
Discounted to 2025 @ 6.89% p.a.
=
CN¥47.56
Fair Value '25
CN¥47.56
Fair Value '25
Converted to HKD @ 1.0927 CNY/HKD Exchange Rate
=
HK$51.97
Fair Value '25
